New Law Expands Pharmacists’ Role In Opioid Use Disorder Treatment
Last Updated:
Author Kristen Fuller, MD
Pharmacists Now Authorized To Prescribe Buprenorphine For Opioid Use Disorder
Although the opioid epidemic continues to affect communities across the U.S., access to opioid treatment is drastically improving and saving lives.
On December 1, 2025, the SUPPORT for Patients and Communities Reauthorization Act of 2025 (HR 2483) was signed into law, allowing pharmacists to independently prescribe and administer buprenorphine, an important and life-changing medication in opioid addiction treatment.
To prescribe buprenorphine, pharmacists must complete 8 hours of training. This training, offered by the American Pharmacists Association (APhA) and the Accreditation Council for Pharmacy Education (ACPE), ensures that all pharmacists are equipped with the appropriate knowledge and skills to safely prescribe and dispense buprenorphine to patients, including those receiving it for the first time.
What Is Buprenorphine?
Buprenorphine is a partial opioid agonist that is FDA-approved to treat opioid use disorder (OUD). It works by binding strongly to the mu opioid receptors in the brain and therefore does not allow other opioids to take effect, preventing the person from getting “high” if they use other opioids, such as heroin.
Buprenorphine also decreases opioid withdrawal symptoms, reduces cravings and urges, and overall increases a person’s success in their opioid addiction treatment journey. Buprenorphine can be used as a long-term maintenance medication and is available in many different formulas, including sublingual tablets or film, buccal films, implants, or injectables, and is often combined with naltrexone.
From MAT Act To HR2483 For Opioid Treatment
Before December 2022, a special “X-waiver” (a federal barrier) was needed to prescribe buprenorphine, limiting who could prescribe this life-changing medication. In 2022, the first major milestone, the Mainstreaming Addiction Treatment (MAT) Act, was passed. This removed the need for the special “X-waiver” to prescribe buprenorphine, allowing more providers, including pharmacists, to offer buprenorphine if they met state-level requirements. However, due to these state-level requirements, many pharmacists were still restricted from prescribing buprenorphine. This is why this new HR2483 legislation is a drastic improvement.
The HR2483 builds on the MAT Act of 2022 by removing any and all state-level variability and explicitly authorizes pharmacists to independently prescribe buprenorphine after they complete the 8-hour training, giving them a more active role in reducing opioid related deaths across the US.
Pharmacists are on the front lines of patient care, and this provision recognizes their critical role in addressing the opioid epidemic. By enabling pharmacists to prescribe buprenorphine with appropriate training, we are expanding access to treatment and saving lives.
Increased Access To Buprenorphine
This new law offers an important new access point for opioid use disorder treatment in many ways:
- People can bypass their doctor’s office. Patients do not have to go to a doctor for a prescription; they can go directly to a pharmacy to receive this medication, even for a first-time prescription.
- The cost is reduced, especially for people without insurance or with high-deductible plans, because there is no need to pay for a doctor visit to get a prescription for buprenorphine.
- It also benefits patients who want to remain anonymous with their opioid treatment and choose not to use their insurance to avoid their employer knowing about their buprenorphine management.
Buprenorphine cost remains a barrier to treatment, as the price of this medication varies widely depending on the pharmacy, whether a brand-name or generic version is used, the route of administration, dosage, and the availability of coupons or savings programs. There are many coupons, prescription discount cards, patient assistance programs, community health centers, and non-profit pharmacies that can help patients save drastically on their monthly buprenorphine prescriptions, increasing their accessibility to this life saving treatment.
Care That's Covered by Insurance
Explore rehabs that accept your insurance today! Start your recovery journey with peace of mind, knowing your care is covered.
Addiction Center is not affiliated with any insurance.
The Opioid Epidemic
The opioid epidemic continues to affect communities across the nation. As of 2024, there are approximately 4.8 million people with an opioid use disorder in the US, which is 1.7% of the U.S. population. In 2023, approximately 79,358 people in the U.S. died from opioid-related overdoses, which accounted for nearly 76% of all drug overdose deaths.
Increasing access to opioid addiction treatment, decreasing stigma surrounding addiction, and spreading awareness and education to the general public are life-saving approaches to help curb the opioid epidemic.
Opioid Treatment
If you or a loved one is struggling with an opioid addiction, treatment is available. Buprenorphine is one of a few different FDA-approved treatment medications for opioid use disorder, often used in conjunction with psychotherapy approaches, which together make up a more comprehensive addiction treatment program.
If you or a loved one is suffering from an addiction to opioids, consider reaching out to a treatment provider or visiting our rehab directory to learn more about your treatment options.